Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Adagrasib oral dose of 400 mg twice daily tablets

Phase 2

MMirati Therapeutics Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced NSCLCActive, not recruiting

Advanced NSCLCPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Advanced NSCLC

NCT05609578

Clinical

Trials by Indication[1]

Advanced NSCLC1 trial

A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Active, not recruiting·MMirati Therapeutics Inc.·Phase 2·NCT05609578·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Adagrasib oral dose of 400 mg twice daily tablets. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Adagrasib oral dose of 400 mg twice daily tablets. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Mirati Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MMirati Therapeutics Inc.

Related News